Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

What Was Tested

The paper reports a study of Peptide YY, published as a randomized controlled trial.

Who Took Part

The abstract describes 1, patients taking part.

PubMed tags the participants as both men and women.

Appetite-regulating gut hormones and appetite ratings during a standard mixed-meal test and effects on subsequent ad libitum food intake were evaluated in two studies: in study 1, nine patients with type 2 diabetes were examined prospectively before and 3 months after RYGB with and without Ex-9.

How the Study Was Run

The design is described as randomized, placebo-controlled and crossover.

The patients were allocated by chance, so the Peptide YY group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Peptide YY group a baseline to be compared against.

In the crossover set-up each of the patients took both Peptide YY and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Appetite, Appetite Regulation, Denmark, Diabetes Mellitus, Type 2, Eating, Gastric Bypass and Glucagon-Like Peptide 1.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Peptide YY in 1, patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (International journal of obesity (2005)), a journal based in England.

More context: the Peptide YY compound page, all human trials.